{
    "componentChunkName": "component---src-templates-docs-js",
    "path": "/literatuur",
    "result": {"data":{"site":{"siteMetadata":{"title":"LTA Antistollingszorg"}},"mdx":{"fields":{"id":"18cf219d-6be7-51fc-aaa2-1fe57cb8b031","title":"Literatuur","slug":"/literatuur"},"body":"var _excluded = [\"components\"];\n\nfunction _extends() { _extends = Object.assign ? Object.assign.bind() : function (target) { for (var i = 1; i < arguments.length; i++) { var source = arguments[i]; for (var key in source) { if (Object.prototype.hasOwnProperty.call(source, key)) { target[key] = source[key]; } } } return target; }; return _extends.apply(this, arguments); }\n\nfunction _objectWithoutProperties(source, excluded) { if (source == null) return {}; var target = _objectWithoutPropertiesLoose(source, excluded); var key, i; if (Object.getOwnPropertySymbols) { var sourceSymbolKeys = Object.getOwnPropertySymbols(source); for (i = 0; i < sourceSymbolKeys.length; i++) { key = sourceSymbolKeys[i]; if (excluded.indexOf(key) >= 0) continue; if (!Object.prototype.propertyIsEnumerable.call(source, key)) continue; target[key] = source[key]; } } return target; }\n\nfunction _objectWithoutPropertiesLoose(source, excluded) { if (source == null) return {}; var target = {}; var sourceKeys = Object.keys(source); var key, i; for (i = 0; i < sourceKeys.length; i++) { key = sourceKeys[i]; if (excluded.indexOf(key) >= 0) continue; target[key] = source[key]; } return target; }\n\n/* @jsxRuntime classic */\n\n/* @jsx mdx */\nvar Text = Typography.Text;\nvar literatureGuidelines = [{\n  title: \"Antitrombotisch beleid\",\n  description: \"Het initiatief voor deze richtlijn is afkomstig van de Nederlandse Internisten Vereniging (NIV). De richtlijn is opgesteld door een multidisciplinaire commissie met vertegenwoordigers vanuit de internisten, huisartsen, orthopeden, longartsen, klinisch chemici, anesthesiologen, cardiologen, traumatologen, kinderartsen, klinisch geriaters, neurologen, gynaecologen, radiologen en laboratoriumartsen. Om het patiëntenperspectief mee te nemen, is in de literatuur gezocht naar artikelen waarin dit perspectief beschreven staat.\",\n  year: \"2016\",\n  url: \"https://richtlijnendatabase.nl/richtlijn/antitrombotisch_beleid/antitrombotisch_beleid_-_korte_beschrijving.html\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Neuraxisblokkade en antistolling\",\n  description: \"Het initiatief voor de richtlijn is afkomstig van de Nederlandse Vereniging voor Anesthesiologie (NVA). De richtlijn is opgesteld door een multidisciplinaire commissie met vertegenwoordigers vanuit de anesthesiologen, internisten/vasculair geneeskundigen, traumachirurgen, ziekenhuisapothekers en hematologen. De werkgroep heeft aandacht besteed aan het patiëntenperspectief door patiëntenbeschrijvingen van bloedingen bij pijnblokkades te bestuderen.\",\n  year: \"2014\",\n  url: \"https://richtlijnendatabase.nl/richtlijn/neuraxisblokkade_en_antistolling/neuraxisblokkade_en_antistolling_-_startpagina.html\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Klinische praktijkrichtlijn ‘bloedige ingrepen in de mondzorg bij patiënten die antitrombotica gebruiken’\",\n  description: \"In de zomer van 2017 is KIMO begonnen met de voorbereiding van de KPR-module Antistolling mondzorg. Deze KPR-module wordt onderdeel van de herziene richtlijn Antitrombotisch beleid van het Kennisinstituut Medisch Specialisten (KIMS).\",\n  year: \"In autorisatie\",\n  url: \"https://www.hetkimo.nl/alle-richtlijnen/\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"ESC guidelines Atrial Fibrillation (Management of)\",\n  description: \"Despite good progress in the management of patients with atrial fibrillation (AF), this arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. These 2016 Atrial Fibrillation Guidelines are based on the current state-of-the-art evidence in 2016.\",\n  year: \"2016\",\n  url: \"https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) 2020\",\n  description: \"Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. A great number of Guidelines\",\n  year: \"2020\",\n  url: \"https://www.escardio.org/static-file/Escardio/Guidelines/Documents/ehaa612.pdf\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Richtlijn antitrombotische therapie en endoscopische procedures\",\n  description: \"Door de Nederlandse Vereniging van Maag-Darm-Leverartsen in samenwerking met leden van de Nederlandse Vereniging voor Cardiologie, Koninklijke Maatschappij ter bevordering der Pharmacie en Nederlandse Internisten Vereniging.\",\n  year: \"2016\",\n  url: \"https://s3.eu-central-1.amazonaws.com/storage.topsite.nl/fnt.nl/uploads/docs/Notities-en-richtlijnen/Richtlijn_antitrombotische_therapie_en_endoscopische_procedures_2016.pdf\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Richtlijn Perioperatief Traject\",\n  description: \"Door de Nederlandse Vereniging van Maag-Darm-Leverartsen in samenwerking met leden van de Nederlandse Vereniging voor Cardiologie, Koninklijke Maatschappij ter bevordering der Pharmacie en Nederlandse Internisten Vereniging.\",\n  year: \"In commentaarfase\",\n  url: \"https://www.anesthesiologie.nl/uploads/files/KD_RL_Concept_Perioperatief_Traject.pdf\",\n  linkName: \"Naar de website\"\n}];\nvar literatureStandards = [{\n  title: \"Landelijke Standaard Keten Antistolling 2.0 (LSKA)\",\n  description: \"De LSKA is inmiddels opgeheven en overgegaan in deze LTA antistollingszorg.\",\n  year: \"2014\",\n  url: \"\",\n  linkName: \"\"\n}, {\n  title: \"NHG standaard diepe veneuze trombose en longembolie\",\n  description: \"De NHG-Standaard Diepe veneuze trombose en longembolie geeft richtlijnen voor de preventie, diagnostiek en behandeling van diepe veneuze trombose en longembolie. Ook tromboflebitis in het been en het posttrombotisch syndroom komen aan bod.)\",\n  year: \"2017\",\n  url: \"https://www.nhg.org/standaarden/volledig/nhg-standaard-diepe-veneuze-trombose-en-longembolie\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"NHG standaard atriumfibrilleren\",\n  description: \"De NHG-Standaard Atriumfibrilleren geeft richtlijnen voor de diagnostiek van en het beleid bij atriumfibrilleren. Atriumfibrilleren is een hartritmestoornis waarbij het ritme volledig onregelmatig en meestal versneld is. De diagnose wordt gesteld op basis van een kenmerkend ECG-beeld. Na extrasystolie is atriumfibrilleren de meest voorkomende hartritmestoornis.\",\n  year: \"2017\",\n  url: \"https://www.nhg.org/standaarden/volledig/nhg-standaard-atriumfibrilleren-tweede-partiele-herziening\",\n  linkName: \"Naar de website\"\n}];\nvar literatureLearning = [{\n  title: \"FRAIL-AF scholing\",\n  description: \"Scholing voor 9 verschillende thema's.\",\n  year: \"2017\",\n  url: \"https://frail-af.nl\",\n  linkName: \"Naar de website\"\n}];\nvar literatureLiterature = [{\n  title: \"Bemt PMLA van den, Egberts ACG. Eindrapport HARM-onderzoek. Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, November 2006.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://www.knmp.nl/downloads/harm-rapport.pdf\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Budnitz DS, Lovegrove MC, Shebab N, Richards CL. Emergency Hospitalizations for Adverse Drug Events in Older Americans. N Engl J Med 2011; 365(21):2002-2012.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://www.nejm.org/doi/full/10.1056/NEJMsa1103053\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"De Kunst van het doseren: Richtlijn, leidraad en informatie voor het doseren van vitamine K-antagonisten (de ‘state-of-the-art’). Federatie Nederlandse Trombosediensten.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://www.fnt.nl/kwaliteit/de-kunst-van-het-doseren\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Hematologieklapper. Staf Hematologie LUMC. 2019.\",\n  description: \"\",\n  year: \"\",\n  url: \"http://www.hematologieklapper.nl\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation; Eur Heart J 2018;39:119–77.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://academic.oup.com/eurheartj/article/39/2/119/4095042\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Khorsand N, et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Transfus Med. 2011 Apr;21(2):116-23.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-3148.2010.01050.x\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Khorsand N, et al. An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica. 2012 Oct;97(10):1501-6.\",\n  description: \"\",\n  year: \"\",\n  url: \"http://www.haematologica.org/content/97/10/1501\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Rahat A. Abdoellakhan, et al. A Randomized Controlled Trial Protocol to Evaluate a Fixed Dose Prothrombin Complex Concentrate against the Variable Dose in Vitamin K Antagonist Related Bleeding (PROPER3) BMJ Open, Vol. 8, No. 3, e020764, 14.03.2018.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://bmjopen.bmj.com/content/8/3/e02076\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39:1330-93.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://academic.oup.com/eurheartj/article/39/16/1330/4942493\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Vademecum Hematologie. Staf Hematologie van het Erasmus MC. 2017.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://www.vademecumhematologie.nl/\",\n  linkName: \"Naar de website\"\n}, {\n  title: \"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017; 39:213-54.\",\n  description: \"\",\n  year: \"\",\n  url: \"https://academic.oup.com/eurheartj/article/39/3/213/4095043\",\n  linkName: \"Naar de website\"\n}];\nvar _frontmatter = {\n  \"title\": \"Literatuur\",\n  \"date\": \"16-10-2025\",\n  \"metaTitle\": \"Literatuur\",\n  \"metaDescription\": \"Een overzicht van de gebruikte richtlijnen, literatuur, standaarden en nascholing.\",\n  \"parent\": \"\",\n  \"type\": \"\",\n  \"previousUrl\": \"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar\",\n  \"previousText\": \"Niet-ernstige bloedingen onder TAR\",\n  \"nextUrl\": \"/colofon/afkortingenlijst\",\n  \"nextText\": \"Afkortingenlijst\"\n};\n\nvar makeShortcode = function makeShortcode(name) {\n  return function MDXDefaultShortcode(props) {\n    console.warn(\"Component \" + name + \" was not imported, exported, or provided by MDXProvider as global scope\");\n    return mdx(\"div\", props);\n  };\n};\n\nvar ListItem = makeShortcode(\"ListItem\");\nvar ListItemMeta = makeShortcode(\"ListItemMeta\");\nvar layoutProps = {\n  Text: Text,\n  literatureGuidelines: literatureGuidelines,\n  literatureStandards: literatureStandards,\n  literatureLearning: literatureLearning,\n  literatureLiterature: literatureLiterature,\n  _frontmatter: _frontmatter\n};\nvar MDXLayout = \"wrapper\";\nreturn function MDXContent(_ref) {\n  var components = _ref.components,\n      props = _objectWithoutProperties(_ref, _excluded);\n\n  return mdx(MDXLayout, _extends({}, layoutProps, props, {\n    components: components,\n    mdxType: \"MDXLayout\"\n  }), mdx(List, {\n    itemLayout: \"vertical\",\n    size: \"large\",\n    bordered: true,\n    style: {\n      marginBottom: \"20px\"\n    },\n    mdxType: \"List\"\n  }, mdx(ListItem, {\n    actions: [mdx(ListUrlAction, {\n      type: \"link\",\n      text: \"156\",\n      link: \"https://www.allesoverantistolling.nl?utm_source=lta-antistollingszorg\",\n      linkName: \"Naar de website\",\n      mdxType: \"ListUrlAction\"\n    })],\n    mdxType: \"ListItem\"\n  }, \"Het Nederlands Kennisplatform Antistolling is een initiatief van de Nederlandse Internisten Vereniging en Trombose Stichting Nederland. Via een website kan de professional en de patient alles over antistolling te weten komen. Het professional gedeelte, dat met een multidisciplinaire werkgroep is gemaakt, bevat via een BIG inlog links naar lokale trombose experts en protocollen als ook landelijke richtlijnen en e-learnings. Het patienten gedeelte bevat antwoorden op veel gestelde vragen over antistollingsmiddelen.\")), mdx(\"h2\", null, \"Richtlijnen\"), mdx(List, {\n    itemLayout: \"vertical\",\n    size: \"large\",\n    bordered: true,\n    dataSource: literatureGuidelines,\n    renderItem: function renderItem(item) {\n      return mdx(ListItem, {\n        key: item.title,\n        actions: [mdx(ListUrlAction, {\n          type: \"link\",\n          text: \"156\",\n          link: item.url,\n          linkName: item.linkName,\n          mdxType: \"ListUrlAction\"\n        })],\n        mdxType: \"ListItem\"\n      }, mdx(ListItemMeta, {\n        title: mdx(\"a\", {\n          href: item.url,\n          target: \"_blank\",\n          rel: \"noreferrer noopener\",\n          style: {\n            \"color\": \"black\"\n          }\n        }, item.title),\n        description: item.description,\n        mdxType: \"ListItemMeta\"\n      }));\n    },\n    mdxType: \"List\"\n  }), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h2\", null, \"Standaarden\"), mdx(List, {\n    itemLayout: \"vertical\",\n    size: \"large\",\n    bordered: true,\n    dataSource: literatureStandards,\n    renderItem: function renderItem(item) {\n      return mdx(ListItem, {\n        key: item.title,\n        actions: [mdx(ListUrlAction, {\n          type: \"link\",\n          text: \"156\",\n          link: item.url,\n          linkName: item.linkName,\n          mdxType: \"ListUrlAction\"\n        })],\n        mdxType: \"ListItem\"\n      }, mdx(ListItemMeta, {\n        title: item.title,\n        description: item.description,\n        mdxType: \"ListItemMeta\"\n      }));\n    },\n    mdxType: \"List\"\n  }), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h2\", null, \"Scholing\"), mdx(List, {\n    itemLayout: \"vertical\",\n    size: \"large\",\n    bordered: true,\n    dataSource: literatureLearning,\n    renderItem: function renderItem(item) {\n      return mdx(ListItem, {\n        key: item.title,\n        actions: [mdx(ListUrlAction, {\n          type: \"link\",\n          text: \"156\",\n          link: item.url,\n          linkName: item.linkName,\n          mdxType: \"ListUrlAction\"\n        })],\n        mdxType: \"ListItem\"\n      }, mdx(ListItemMeta, {\n        title: item.title,\n        description: item.description,\n        mdxType: \"ListItemMeta\"\n      }));\n    },\n    mdxType: \"List\"\n  }), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h2\", null, \"Literatuur\"), mdx(List, {\n    itemLayout: \"vertical\",\n    size: \"large\",\n    bordered: true,\n    dataSource: literatureLiterature,\n    renderItem: function renderItem(item) {\n      return mdx(ListItem, {\n        key: item.title,\n        actions: [mdx(ListUrlAction, {\n          type: \"link\",\n          text: \"156\",\n          link: item.url,\n          linkName: item.linkName,\n          mdxType: \"ListUrlAction\"\n        })],\n        mdxType: \"ListItem\"\n      }, mdx(ListItemMeta, {\n        title: item.title,\n        description: item.description,\n        mdxType: \"ListItemMeta\"\n      }));\n    },\n    mdxType: \"List\"\n  }));\n}\n;\nMDXContent.isMDXComponent = true;","tableOfContents":{"items":[{"url":"#richtlijnen","title":"Richtlijnen"},{"url":"#standaarden","title":"Standaarden"},{"url":"#scholing","title":"Scholing"},{"url":"#literatuur","title":"Literatuur"}]},"parent":{"relativePath":"literatuur.mdx"},"frontmatter":{"parent":"","date":"16-10-2025","nextUrl":"/colofon/afkortingenlijst","nextText":"Afkortingenlijst","previousUrl":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar","previousText":"Niet-ernstige bloedingen onder TAR"}},"allMdx":{"edges":[{"node":{"fields":{"slug":"/afbakening","title":"Afbakening"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica","title":"Bloedingen onder antitrombotica"}}},{"node":{"fields":{"slug":"/colofon","title":"Colofon"}}},{"node":{"fields":{"slug":"/contact","title":"Contact"}}},{"node":{"fields":{"slug":"/inleiding","title":"Inleiding"}}},{"node":{"fields":{"slug":"/colofon/afkortingenlijst","title":"Afkortingenlijst"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/gezamenlijke-besluitvorming","title":"Gezamenlijke besluitvorming"}}},{"node":{"fields":{"slug":"/colofon/verantwoording","title":"Verantwoording"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/informatievoorziening","title":"Informatievoorziening"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/therapietrouw","title":"Therapietrouw"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/veelgestelde-vragen-over-doacs","title":"Veelgestelde vragen over DOACs"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/overzicht-periprocedureel-bloedingsrisico","title":"Overzicht periprocedureel bloedingsrisico"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/overzicht-trombo-embolie-risico","title":"Overzicht trombo-embolie risico"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-factor-xa-remmers-rivaroxaban-apixaban-edoxaban","title":"Beslisboom DOAC - factor Xa-remmers, Rivaroxaban, Apixaban, Edoxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-beleid-bij-bloedingen-voor-de-huisarts","title":"Beslisboom Beleid bij bloedingen voor de huisarts"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-doac","title":"Beslisboom DOAC"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-apixaban","title":"Beslisboom Apixaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/bloeding-onder-lmwh-ongefractioneerde-heparine","title":"Bloeding onder LMWH/ ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-rivaroxaban","title":"Beslisboom Rivaroxaban"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-prasugrel-clopidogrel-ticagrelor","title":"Beslisboom DAPT ASA en prasugrel, clopidogrel, ticagrelor"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-dipyridamol","title":"Beslisboom DAPT ASA en dipyridamol"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-monotherapie-clopidogrel-of-asa","title":"Beslisboom monotherapie Clopidogrel of ASA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/minimale-duur-onderbreken-en-herstarten-dapt","title":"Minimale duur onderbreken en herstarten DAPT"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/doac/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/doac/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/lmwh/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/tar/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/tar/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-edoxaban","title":"Beslisboom Edoxaban"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/vka/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/vka/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-dabigatran/schematisch","title":"Beslisboom DOAC- dabigatran"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-tar/schematisch","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-doac/schematisch","title":"Beslisboom DOAC"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-apixaban/schematisch","title":"Beslisboom Apixaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar/schematisch","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-dabigatran/schematisch","title":"Beslisboom Dabigatran"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-rivaroxaban/schematisch","title":"Beslisboom Rivaroxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-factor-xa-remmers-rivaroxaban-apixaban-edoxaban/schematisch","title":"Beslisboom DOAC - factor Xa-remmers, Rivaroxaban, Apixaban, Edoxaban"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-edoxaban/schematisch","title":"Beslisboom Edoxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-beleid-bij-bloedingen-voor-de-huisarts/schematisch","title":"Beslisboom Beleid bij bloedingen voor de huisarts"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-dipyridamol/schematisch","title":"Beslisboom DAPT ASA en dipyridamol"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-monotherapie-clopidogrel-of-asa/schematisch","title":"Beslisboom monotherapie Clopidogrel of ASA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-prasugrel-clopidogrel-ticagrelor/schematisch","title":"Beslisboom DAPT ASA en prasugrel, clopidogrel, ticagrelor"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/dual-antiplatelet-therapy-dapt-behandeling","title":"Dual Antiplatelet Therapy (DAPT) behandeling"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/aanbevelingen-overbrugging-en-herstarten-vka","title":"Aanbevelingen overbrugging en herstarten VKA"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/lmwh/dosering-lmwh-bij-verminderde-nierfunctie","title":"Dosering LMWH bij verminderde nierfunctie"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/hoog-complexe-antistolling","title":"Hoog complexe antistolling"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/laag-complexe-antistolling","title":"Laag complexe antistolling"}}},{"node":{"fields":{"slug":"/literatuur","title":"Literatuur"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-dabigatran","title":"Beslisboom DOAC - dabigatran"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/extra-opmerkingen-tandheelkundige-ingrepen","title":"Extra opmerkingen tandheelkundige ingrepen"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-dabigatran","title":"Beslisboom Dabigatran"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/veelgestelde-vragen-over-vka","title":"Veelgestelde vragen over VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine/schematisch","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-tar","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine/schematisch","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/changelog","title":"Changelog"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/","title":"Welkom!"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/extra-opmerkingen-endoscopische-ingrepen","title":"Extra opmerkingen endoscopische ingrepen"}}}]}},"pageContext":{"id":"18cf219d-6be7-51fc-aaa2-1fe57cb8b031"}},
    "staticQueryHashes": ["1620603387","2744294623","3578633366","3706406642","4066733661"]}